Scientists stressed on the need for larger phase 3 trials to examine the effectiveness of this triple combination in critically ill patients, adding that these early findings were only observed in patients with mild to moderate illness Beijing: A two-week course of an antiviral therapy, started within seven days of experiencing COVID-19 symptoms, may improve clinical recovery of patients and reduce their hospital stay duration, according to the first randomised trial of this triple drug combination.
The study, published in the journal The Lancet, involved 127 adults from six public hospitals in Hong Kong, and tested the effectiveness of an antiviral drug combination in reducing the load of the novel coronavirus in their bodies.